Trial Profile
FOCUS follow up of clinical outcomes: the long-term AGI-1067 [succinobucol] plus usual care study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Succinobucol (Primary)
- Indications Coronary artery disease
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS
- Sponsors AtheroGenics
- 14 Mar 2007 New trial record.